Cardiol Therapeutics (CRDL) vs Molecular Partners (MOLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cardiol Therapeutics (CRDL) has outperformed Molecular Partners (MOLN) over the past year, gaining 24.5% versus a gain of 2.7%. Over five years, CRDL leads with a -66.4% price change compared with -80.8% for MOLN. Cardiol Therapeutics is the larger company by market cap ($160.4 million vs $145.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDL | MOLN |
|---|---|---|
| Share price | $1.32 | $3.81 |
| Market cap | $160.40M | $145.94M |
| 1-day change | +0.76% | +0.79% |
| YTD return | +38.36% | -12.59% |
| 1-year return | +24.53% | +2.70% |
| 5-year return | -66.41% | -80.76% |
| EPS (TTM) | $-0.25 | $-1.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.34 | $5.36 |
| 52-week low | $0.88 | $3.53 |
| Distance from 52-week high | -43.59% | -28.92% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +533.33% | +172.18% |
| Average volume | 1.39M | 1.20K |
| Shares outstanding | 121.51M | 38.31M |
| Employees | 18 | 134 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDL has outperformed MOLN by 21.8 percentage points over the past year.
About Cardiol Therapeutics
CRDL stock →Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Healthcare · Drug Manufacturers - Specialty & Generic · 18 employees
About Molecular Partners
MOLN stock →Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.
Healthcare · Biotechnology · 134 employees
CRDL vs MOLN FAQ
Which is bigger, Cardiol Therapeutics or Molecular Partners?
Cardiol Therapeutics (CRDL) is larger, with a market capitalization of $160.40M compared with $145.94M for Molecular Partners (MOLN).
Which stock has performed better over the past year, CRDL or MOLN?
CRDL returned +24.53% over the past 12 months, compared with +2.70% for MOLN (price return, excluding dividends). Past performance does not predict future results.
Are Cardiol Therapeutics and Molecular Partners in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for Cardiol Therapeutics and Biotechnology for Molecular Partners.